Navigation Links
FDA Statement on Makena
Date:11/8/2011

SILVER SPRING, Md., Nov. 8, 2011 /PRNewswire-USNewswire/ -- FDA approved Makena (hydroxyprogesterone caproate) in February 2011 for the reduction of the risk of certain preterm births in women who have had at least one prior preterm birth.  For many years before Makena was approved, a version of the active ingredient of Makena has been available to patients whose physicians requested the drug from a pharmacist who compounded the drug.  In March 2011, after learning that the owner of Makena, K-V Pharmaceuticals, had sent letters to pharmacists indicating that FDA will no longer exercise enforcement discretion with regard to compounded versions of Makena, FDA issued a statement about compounded hydroxyprogesterone caproate to clarify the agency's enforcement priorities.  In the March 2011 statement, FDA explained that the agency prioritizes enforcement actions related to compounded drugs using a risk-based approach, giving the highest enforcement priority to pharmacies that compound products that are causing harm or that amount to health fraud.  The agency also stated:

(Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO)

In order to support access to this important drug, at this time and under this unique situation, FDA does not intend to take enforcement action against pharmacies that compound hydroxyprogesterone caproate based on a valid prescription for an individually identified patient unless the compounded products are unsafe, of substandard quality, or are not being compounded in accordance with appropriate standards for compounding sterile products. As always, FDA may at any time revisit a decision to exercise enforcement discretion.

In October 2011, FDA received information from K-V Pharmaceuticals regarding the potency and purity of samples of bulk hydroxyprogesterone caproate active pharmaceutical ingredients (APIs) and compounded hydroxyprogesterone caproate products.  According to the analysis of this information provided by K-V, there is variability in the purity and potency of both the bulk APIs and compounded hydroxyprogesterone caproate products that were tested.  Although FDA has not validated or otherwise confirmed the analyses provided by K-V, FDA has carefully reviewed the data and will conduct an on-site review of the laboratory analyses.

FDA has begun its own sampling and analysis of compounded hydroxyprogesterone caproate products and the bulk APIs used to make them.  That process is ongoing.  In the meantime, we remind physicians and patients that before approving the Makena new drug application, FDA reviewed manufacturing information, such as the source of the API used by its manufacturer, proposed manufacturing processes, and the firm's adherence to current good manufacturing practice.   Therefore, as with other approved drugs, greater assurance of safety and effectiveness is generally provided by the approved product than by a compounded product.

Media Inquiries: Shelly Burgess, 301-796-4651, shelly.burgess@fda.hhs.gov


'/>"/>
SOURCE U.S. Food and Drug Administration
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Cempra Holdings, LLC Files Registration Statement for Proposed Initial Public Offering
2. Alere Inc. Statement Regarding Recommended Increased Cash Offer to Acquire Axis-Shield
3. Alere Inc. Statement Regarding Axis-Shield Offer
4. Alere Inc. Statement Amending Acceptance Condition to Axis-Shield Offer
5. Visual Healthcare Corp. Files Year-End Disclosure Statement
6. Statement from the Michigan Society of Anesthesiologists in Response to Governor Snyders Health & Wellness Announcement
7. Vycor Medical, Inc. Files Restated Financial Statements
8. Vycor Medical, Inc. Restatement of Financial Statements
9. Argos Therapeutics Files Registration Statement for Proposed Initial Public Offering
10. Statement on Availability of Primatene® Mist CFC
11. Jonah and Dina Shacknai Issue Statement Regarding the Release of Paradise Valley Police Reports
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... NeuroVive Pharmaceutical AB (Nasdaq Stockholm: ... preclinical results demonstrating anti-fibrotic effects with NV556, ... (NASH), in an additional well-validated experimental NASH ... previously shown similar anti-fibrotic effects in the ... present novel data demonstrating anti-fibrotic effects of ...
(Date:4/19/2017)... Cardiology devices segment is anticipated to reach the ... Cardiology Devices segment is likely to create absolute $ opportunity ... over 2017. By the end of 2027, Cardiology Devices segment ... 700 Mn, expanding at a CAGR of 18.4% over the ... Asia Pacific reprocessed medical devices market in terms ...
(Date:4/19/2017)... NEW YORK , April 19, 2017 ... Surgical drainage devices are tubes used to remove excess ... include, blood, serum, pus, urine, bile or lymph. Surgical ... types of surgery such as orthopedics surgery, cardiovascular surgery, ... device is prophylactic post-surgery to prevent accumulation of fluid ...
Breaking Medicine Technology:
(Date:4/22/2017)... , ... April 22, 2017 ... ... of Eastern Pennsylvania has named PROSHRED® Security of Philadelphia its “Woman-Owned ... PROSHRED® Philadelphia specializes in providing information destruction , recycling, and ...
(Date:4/21/2017)... , ... April 21, 2017 , ... An April 10 ... a pair of ancient teeth, which reveal a great deal about prehistoric ice-age dental ... sharp stone may have been used to remove decayed dental matter, and that teeth ...
(Date:4/21/2017)... ... April 21, 2017 , ... Chicago plastic surgeon, Dr. Anil R. ... osteoma is a benign bony lump located on the forehead usually attributed to a ... with sight and pain. Dr. Shah has discovered an approach that is minimally invasive. ...
(Date:4/21/2017)... ... 21, 2017 , ... Dudnyk has announced the launch of its new brand ... full potential of specialty and orphan brands can only be achieved when the needs ... Unifying Effect is at the heart of a true partnership between our agency and ...
(Date:4/21/2017)... ... , ... The Hong Kong Polytechnic University (PolyU) launched today the University Research ... in Hong Kong to support teaching, learning and research. It is also the largest ... in Hong Kong. , With an area of 620 square metres and more ...
Breaking Medicine News(10 mins):